Toronto Dominion Bank increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 12.6% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 99,771 shares of the pharmaceutical company’s stock after purchasing an additional 11,138 shares during the period. Toronto Dominion Bank’s holdings in Vertex Pharmaceuticals were worth $15,169,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of VRTX. Jennison Associates LLC boosted its stake in Vertex Pharmaceuticals by 253.8% in the 2nd quarter. Jennison Associates LLC now owns 5,055,122 shares of the pharmaceutical company’s stock worth $651,454,000 after purchasing an additional 3,626,368 shares during the period. Old Mutual Global Investors UK Ltd. boosted its stake in Vertex Pharmaceuticals by 1,384.7% in the 2nd quarter. Old Mutual Global Investors UK Ltd. now owns 1,195,455 shares of the pharmaceutical company’s stock worth $154,058,000 after purchasing an additional 1,114,939 shares during the period. Assenagon Asset Management S.A. boosted its stake in Vertex Pharmaceuticals by 9,422.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 893,380 shares of the pharmaceutical company’s stock worth $135,829,000 after purchasing an additional 883,998 shares during the period. AJO LP acquired a new position in Vertex Pharmaceuticals in the 2nd quarter worth approximately $71,956,000. Finally, Vanguard Group Inc. boosted its stake in Vertex Pharmaceuticals by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company’s stock worth $2,188,196,000 after purchasing an additional 504,982 shares during the period. 92.79% of the stock is owned by hedge funds and other institutional investors.
In other news, EVP Stuart A. Arbuckle sold 6,290 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $143.97, for a total transaction of $905,571.30. Following the sale, the executive vice president now directly owns 116,952 shares in the company, valued at approximately $16,837,579.44. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP David Altshuler sold 1,796 shares of Vertex Pharmaceuticals stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $160.00, for a total transaction of $287,360.00. Following the sale, the executive vice president now owns 107,807 shares in the company, valued at $17,249,120. The disclosure for this sale can be found here. Insiders sold a total of 220,094 shares of company stock worth $32,074,719 over the last 90 days. Company insiders own 1.80% of the company’s stock.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down $0.71 during midday trading on Tuesday, reaching $148.03. 743,600 shares of the company’s stock traded hands, compared to its average volume of 1,824,147. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01. The firm has a market cap of $37,616.77, a price-to-earnings ratio of 247.90, a price-to-earnings-growth ratio of 3.78 and a beta of 1.63. Vertex Pharmaceuticals Incorporated has a 52 week low of $71.46 and a 52 week high of $167.85.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.49. The company had revenue of $578.20 million for the quarter, compared to analyst estimates of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The business’s quarterly revenue was up 39.7% on a year-over-year basis. During the same period last year, the business posted $0.16 EPS. sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 0.72 earnings per share for the current year.
VRTX has been the subject of a number of research analyst reports. Cowen and Company reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, August 1st. Zacks Investment Research downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Credit Suisse Group increased their target price on shares of Vertex Pharmaceuticals from $125.00 to $195.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 19th. DA Davidson initiated coverage on shares of Vertex Pharmaceuticals in a research report on Friday, September 29th. They issued a “buy” rating and a $200.00 target price for the company. Finally, Jefferies Group LLC reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, August 22nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-three have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $173.15.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.